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Objective: To understand the role of WFDC2 in metastasis of ovarian cancer.
Methods: By knockdown or overexpression of WFDC2, we demonstrated the role of
WFDC2 in epithelial–mesenchymal transition (EMT).
Results: We demonstrated that stable knockdown of WFDC2 suppressed EMT along with
the upregulation of E-cadherin and the downregulation of Vimentin. In addition, WFDC2
knockdown decreases matrix metalloproteinase-2 (MMP-2) expression in in vitro cell model
and in in vivo nude mice xenografts. The correlation of WFDC2 and MMP-2 expression in
the clinical sample confirmed that WFDC2 was tightly correlated with the development of
tumor. More importantly, the EMT phenotype and cell invasion induced by WFDC2
overexpressing can be reversed by the siMMP-2 and P13K/AKT signaling inhibitor.
Conclusion: WFDC2 contributed to ovarian cancer metastasis and EMT as a positive
regulator by activating AKT signaling pathway and inducing MMP-2 expression.
Keywords: WFCD2, ovarian cancer, metastasis, cell migration and invasion, epithelial-
mesenchymal transition
Background
The expanding knowledge of cancer biology has led to improved understanding of
the molecular mechanisms of ovarian cancer and advancement of targeted thera-
peutics. WFDC2 (WAP four-disulfide core domain protein 2), which encodes
human epididymis secretory protein 4 (HE4), had been followed with interest as
a new serine protease inhibitor belonging to the WAP family. While WAP-type
proteins had been identified to be closely related to tumor metastasis by more and
more evidence, especially SLPI and P13 (encode secretory leukocyte protease
inhibitor[SLPI] and Elafin, respectively).1–4 Our former work had shown that
WFDC2 is a survival factor for ovarian cancer and its increased expression is
associated with malignant and metastasis advantages both in vitro and in vivo.1,5,21
Otherwise, its physiological and pathological mechanisms in tumorigenesis and
metastasis have not been elucidated.
Epithelial–mesenchymal transition (EMT) is a critical process in the metastatic
cascade, which is characterized by a fundamental change in cellular morphology
and phenotype with increased ability to migrate.6,7 In recent years, several studies
have reported the role of EMT in cancer malignancy.6,7 and it has been established
as a key regulator in many types of cancers including ovarian cancer.8 However, the
mechanisms of EMT regulation in ovarian cancer are still unclear.
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In our former study, we had observed the expression of
apoptosis and metastasis-related gene expression in
WFDC2 knockdown cells.5 To be interesting, WFDC2
knockdown decreased the expression of matrix metallo-
proteinase-2 (MMP-2) expression in ovarian cancer cells.
As all known, tumor metastasis occurs secondary to tumor
cell adhesion, migration, and proteolytic degradation of
the extracellular matrix (ECM). MMPs, especially MMP-
2 and MMP-9, are prognostic for metastatic potential and
outcome in ovarian cancer.11–13 MMPs also are essential
factors of selectively modulating the tumor microenviron-
ment to promote tumor cell metastasis and is considered as
an inducer of EMT.14–17 Bouchad et al reported that
WFDC2 is co-expressed with other WAP structure genes
(SLPI and Elafin) on chromosome 20q12-13.1 locus.18
Hoskins et al had reported that SLPI secretion upregulates
MMP-9 transcription and secretion in ovarian cancer
cells.19 Choi also showed that SLPI is associated with
MMP-2 and MMP-9 to promote migration and invasion
in cancer cells.20 In view of the above information, we
speculated that WFDC2 may play some role in the ovarian
cancer microenvironment rebuilding and promote cell
EMT and invasive behavior by regulating MMP-2
expression.
In the present study, we would identify whether
WFDC2 overexpression induced ovarian cancer cell lines
to undergo EMT and promoted cell migration and invasion
through regulating MMP-2 expression, making WFDC2 a
potential target for gene therapy.
Methods
Cell line and regents
Human ovarian cancer cell lines SKOV3, HO8910, and
OVACAR8 were obtained from Shanghai Institute for
Biological Sciences, Chinese Academy of Sciences. All
cells were cultured in RPMI-1640 supplemented with
10% FBS and antibiotics (Gibco BRL, Rockville, MD,
USA) in an atmosphere of 5% CO2 at 37°C. The P13K/
Akt inhibitor LY294002 (CST, MA, USA) was purchased
commercially. Transwell system was purchased from
CostarCorning (Corning, NY, USA); puromycin and tri-
zol reagent from Invitrogen (Life Technologies, Carlsbad,
CA, USA); and cell culture media (antibiotic, serum, and
glutamine) from GIBCO (Life Technologies, Carlsbad,
CA, USA). All other molecular reagents and solvents
were purchased from SIGMA Corp (St. Louis,
MO, USA).
RNA interference and overexpression
transfection
WFDC2 (NM_001039348) cDNA was inserted into
PcDNA3.1 vetor to construct the recombination plasimid
to achieve the overexpression WFDC2 in ovarian cancer
cells, while knockdown of WFDC2 was achieved with
cloning small hairpin RNAs (shRNAs) used self-inactivat-
ing lentivirus vector containing a CMV-driven GFP reporter
(Genepharma Co. Ltd, Shanghai, China). The target
sequence for WFDC2 was (5ʹ-
GCTCTCTGCCCAATGATAAGG-3ʹ) and the invalid
RNAi sequence was (5ʹ-GTTCTCCGAACGTGTCACGT-
3ʹ).5 Small RNAs (siRNAs) against MMP-2 was also con-
structed by Shanghai Genepharma Co. Ltd. The results of
western blotting and real-time quantitative RT-PCR further
confirmed the transfection efficiency.
RNA extraction and real-time RT-PCR
Total RNAwas isolated following the manufacturer’s instruc-
tions (PrimeScript 1st Strand cDNA Synthesis Kit,
TAKARA). The β-actin was used to evaluate the efficiency
and variability of the reverse transcription step. cDNA samples
(0.1 μg) were amplified under conditions recommended by the
manufacturer SYBR Green PCRMaster Mix (TAKARA): (a)
preincubation at 95°C for 1 min; (b) 40 PCR cycles of 95°C
for 10 s, and 55°C for 30 s, 70 °C for 30 s.
Western blot
Protein lysates were fractionated on SDS-polyacrylamide gels
and transferred to polyvinylidene fluoride (PVDF) membrane
and blocked with 5% skimmed milk in Tris-buffered saline
with Tween 20. The primary antibodiesWFDC2, MMP-2, E-
cadherin, Vimentin, AKT, ERK, p-AKT, p-ERK, snail, slug,
and smad3 were purchased from Cell Signaling Co. Ltd (CST,
MA, USA). All antibodies (dilution 1:1,000) were incubated
on shaking bed overnight at 4°C, respectively. Secondary
antibody (dilution 1:1,000) was incubated at room
temperature for 30 mins. Developed films were digitized by
scanning, and the densitometric quantification of protein bands
was performed with GAPDH as an internal control.
Cell invasion assay
Transwell polycarbonate plates with 6.5 mm diameter tissue
culture inserts containing a membrane with 8 μm pores were
used for migration and invasion assay (Corning, NY, USA).
The cells were cultured in serum-free DMEM medium over-
night before the initiation of the experiments. 1×105 cells were
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seeded into each insert which was precoated with (for the
invasion assay) Matrigel (Corning, NY, USA). The DMEM
medium with 10% FBS was added to each outer well. The
plates were then assembled and incubated for 18 hrs at 37°C,
5%CO2. After an 18 hr incubation, the plates were rinsed once
in PBS, fixed in 70% alcohol for 10 mins, and rinsed with
0.5% crystal violet. The number of cells was counted, and
images were obtained under a microscope (100×
magnification).
Immunocytochemistry (ICC)
Cells were seeded into 6-well plate with coverslips inside.
After appropriate culture, the coverslips were rinsed once in
PBS with tween, then fixed in 70% alcohol for 10 mins. The
coverslips were incubated with E-cadherin and Vimentin
antibodies with dilution rate 1:50 at 4°C for 2 hrs followed
by washing with 1× PBS pH 7.4. After washing, the cells
were incubated with the secondary antibody. After three
washing with 1× PBS, cover slides were analyzed with
fluorescence microscope at 200× and 400× magnification.
Immunohistochemistry (IHC)
Immunohistochemistry analysis was performed as previously
described.11 Anti-WFDC2 antibody and anti-MMP-2 antibody
were applied to the slides at a dilution of 1:50 in blocking
buffer overnight at 4°C. The slides were then washed and
stained by the avidin-biotin method. The slides were lightly
counterstained with hematoxylin. The intensity was scored as
negative (0), weak (1), medium (2), and strong (3), and the
proportion of staining was scored as 1 (≤10%), 2 (11–50%), 3
(51–75%), and 4 (>75%). An overall expression score was
calculated by multiplying the scores for intensity and propor-
tion, ranging from 0 to 12.
Statistical analysis
The results were expressed as the mean ± SE. The statis-
tical software SPSS13.0 (SPSS Inc., Chicago, IL, USA)
was used in data processing and analyzing the significance
with the one-way ANOVA or unpaired t-test. P-value
<0.05 was considered statistically significant.
Results
WFDC2 knockdown suppresses the
expression of MMP-2
Previous data have shown that WFDC2 knockdown sig-
nificantly attenuates migration and invasiveness of ovarian
cancer cells.5,21 MMPs, especially MMP-2 and MMP-9,
can degrade the ECM to regulate cell migration and
invasion.16–21 In these studies, we detected the expression
of MMPs by real-time RT-PCR. The results indicated that
the expression of MMP-2 was downregulated by WFDC2
knockdown (Figure 1A). Then by the means of Western
blot and IHC, we have shown that knockdown of WFDC2
inhibits MMP-2 expression both in vitro and in vivo.
MMP-2 was obvious downregulated by WFDC2 knock-
down both in cell model and xenograft of ovarian cancer
cells (Figure 1B and C). To further confirm the correlation
with WFDC2 and MMP-2, we also examined the expres-
sion of WFDC2 and MMP-2 in clinical samples with IHC
and did the correlation assay. As shown in Figure 1D, a
positive correlation between MMP-2 and WFDC2
expression was observed in 100 ovarian cancer patients
(tumor characteristics for ovarian cancer patient see in
Table S1 or reference21).
WFDC2 promotes cell metastasis by
upregulating EMT
Knockdown of WFDC2 in HO8910 and SKOV3 cells
inhibits cell migration and invasion,5 but the mechanism
remains to be studied. In the current study, we further
aimed to investigate the effects of WFDC2 on EMT,
which is important in the initiation and promotion of cell
migratory and invasive properties. First, the expression of
EMT markers was analyzed in WFDC2 knockdown ovar-
ian cancer cells and the control, respectively. As shown in
Figure 2A, knockdown of WFDC2 increased the expres-
sion of E-cadherin, whereas the expression of Vimentin
was downregulated. The important regulator of EMT,
Slug, and Snail was also decreased by WFCD2 knock-
down. Herein, Smad3, a protein involved in TGF-β and
activin-mediated growth modulation, were also decreased
by WFCD2 knockdown (Figure 2B). These data indicated
that WFCD2 is involved in EMT regulation. Moreover,
immunofluorescence microscopy confirmed increased
levels of E-cadherin and decreased levels of Vimentin in
WFCD2 knockdown HO8910 cells compared with control
cells (Figure 2C). The further immunohistochemical ana-
lysis of xenograft tumor sections revealed an acquisition of
the epithelial nature of the tumor as evidenced by
increased E-cadherin expression and decreased levels of
Vimentin following WFCD2 knockdown in HO8910 cells
(Figure 2D). The above results indicate a significant cor-
relation between WFCD2 and the expression of the bio-
chemical markers E-cadherin and Vimentin. Taken
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together, these results indicate that WFCD2 is crucial to
maintain epithelial characteristics for ovarian cancer and
might play some role in EMT.
WFDC2 promotes invasion of ovarian
cancer cells in an MMP-2-dependent
manner
As cell metastasis had been suppressed by WFDC2
knockdown in serous ovarian cancer cells, then we
examined whether cellular motility could be promoted by
overexpression of WFDC2. According to the endogenous
basal level of WFDC2 in different ovarian cancer cells,
OVACAR8 were chosen for WFDC2 overexpression
experiments.5 Thus, the PcDNA3.1/WFDC2 plasmid was
constructed and transfected into OVACAR8 cells.
Compared with the control cells, the expression of
WFDC2 was dramatically upregulated in OVACAR8/
WFDC2 cells, which was assessed by Western blotting
(Figure 3A). To declare whether MMP-2 truly participates
in the metastasis induced by WFDC2, siMMP-2 (a siRNA
especially against MMP-2) was used to treat the
OVACAR8/WFDC2 and the control cells and the invasion



















































































































Figure 1 WFDC2 knockdown suppressed the expression of MMP-2. (A) Real-time RT-PCR analysis of MMP-2 in SK-OV-3 and HO8910 cells expressing sh-GFP or sh-
WFDC2, *P<0.05 compared to sh-GFP group; (B) Western blot analysis of MMP-2 in SK-OV-3 and HO8910 cells expressing sh-GFP or sh-WFDC2; *P<0.05 compared to sh-
GFP group; (C) MMP-2 immunohistochemistry in sh-GFP or sh-WFDC2 xenografts; normalized E-cadherin and Vimentin protein levels in sh-GFP or sh-WFDC2 xenografts.
*P<0.05 compared to sh-GFP group; (D) Representative images of MMP-2 and WFDC2 expression in normal ovarian tissue and primary ovarian cancer tissues are shown
(200×magnificaiton); Correlation analysis between WFDC2 and MMP-2 level score in ovarian cancer tissues.
Abbreviations: MMP, matrix metalloproteinase; sh, small hairpin.
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Remarkably, overexpression of WFDC2 increased
invasion of OVACAR8 cells, while inhibition of MMP-2
rescued the effect of WFDC2 overexpression on cellular
invasion (Figure 3B–C). The results suggest that MMP-2,
one of the most important EMT promotors, may be a
direct downstream target of WFDC2.
Then, we used siMMP-2 to determine the role of
MMP2 in tumor cell metastasis and EMT induced by
WFDC2. As shown in Figure 3C, the expression level
of E-cadherin was also increased in siMMP-2-treated
cells compared with in control cells, whereas the expres-
sion of Vimentin was decreased (Figure 3C). These data
suggest that the WFDC2 may act as an important role in
ovarian cancer metastasis and EMT in association with
MMP-2.
WFDC2 promotes cell migration and
EMT by regulating the AKT pathway in
human ovarian carcinoma cells
To further illustrate the molecular mechanism of
WFDC2 on cell migration and EMT, we verified
whether the P13K/AKT and MAPK/ERK signaling pro-

















































































































Figure 2 WFDC2 regulates EMT in ovarian cancer. (A) Western blot analysis of EMT markers (E-cadherin and Vimentin) in SK-OV-3, and HO8910 cells expressing
negative control or shRNA, *P<0.05 compared to sh-GFP group. (B) Western blot analysis of EMT regulators (smad3, Snail, and Slug) in SK-OV-3, and HO8910 cells
expressing sh-GFP or sh-WFDC2. (C) E-cadherin and Vimentin immunofluorescence in sh-GFP or sh-WFDC2 cells. (D) E-cadherin and Vimentin immunohistochemistry in
sh-GFP or sh-WFDC2 xenografts; normalized E-cadherin and Vimentin protein levels in sh-GFP or sh-WFDC2 xenografts. *P<0.05 compared to sh-GFP group in HO8910.
Abbreviations: sh, small hairpin; EMT, epithelial–mesenchymal transition.
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shown in Figure 4A, WFDC2 knockdown had
obviously inhibition effect on the AKT phosphoryla-
tion (Figure 4A) but not on ERK (data not shown).
And overexpression of WFDC2 promotes AKT phos-
phorylation as expected (Figure 4B).
We then used the P13K/AKT signaling inhibitor
LY294002 to inhibit the phosphorylation of AKT in
OVACAR8/WFDC2 cells and performed an invasion
assay to assess the impact of the WFDC2 on cellular
invasion through P13K/Akt signaling. As shown in
Figure 4C, LY294002 attenuated the cellular invasion of
OVACAR8/WFDC2 cells. By treatment by LY294002 (20
μmol/L), we had observed the inhibition of phosphoryla-
tion of AKT and the expression of MMP-2. We also
observed the expression level of E-cadherin was also
increased in LY294002-treated cells, while Vimentin was
decreased compared with control cells (Figure 4D)
All these data suggest the relationship between
WFDC2, MMP-2, and AKT signaling pathway. Our
study shows that WFDC2 promotes an EMT through the
activation of the AKT signaling, leading to the enhanced
invasion, migration, and metastasis of serous ovarian can-
cer cells. Since knockdown of MMP-2 and inhibition of
the AKT signaling could inhibit the motility of cells with
WFDC2 overexpression, we propose that AKT and MMP-
2 are downstream targets of WFDC2, WFDC2 might acti-
vate the AKT signaling to exert MMP-2 and the promoter
of EMT and facilitate important functions on ovarian can-
cer metastasis and (Figure 4E).
Discussion
As the highest lethal gynecological tumors, pathogen-
esis mechanism of ovarian cancer is not very clear as
that in lung cancer, liver cancer and breast cancer.
WFDC2 is known to be highly expressed in ovarian
cancer cells and is considered to be a biomarker of
ovarian cancer, but its role in the development of














































































































Figure 3 WFDC2 promote cell invasion in a MMP-2-dependent manner. (A) Overexpression of WFDC2 detected by Western blotting in OVACAR8 cell lines. *P<0.05
compared to OVACAR8/NA, #P<0.05 compared to OVACAR8. (B) Invasion of OVACAR8 cells was inhibited by siMMP-2 by transwell invasion assay with Matrigel
(*P<0.05, compared to OVACAR8 cells with WFDC2 expression). Histogram plots are representative of the number of cells that invaded through the transwell
membranes. (C) Detection of MMP-2, Vimentin, and E-cadherin in OVAVAR8 cells treated with siMMP-2.
Abbreviations: MMP, matrix metalloproteinase; sh, small hairpin.
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work, we had illustrated the potential clinical relevance
of WFCD2 to ovarian cancer progression, and the
results show that increased expression of WFCD2 cor-
related with the malignant and peritoneal metastasis of
serous ovarian cancer. By means of the shRNA
method, we found that knockdown WFDC2 can inhibit
ovarian cancer metastasis and transplant both in vivo
















































































































































Figure 4 WFDC2 promotes cell migration and EMT by regulating the AKT pathway in human ovarian carcinoma cells. Knockdown of WFDC2 suppressed P13K/AKT
signaling but not MAPK/ERK signaling (*P<0.05 compared to sh-GFP group). (B) Overexpression of WFDC2 activated P13K/AKT signaling (*P<0.05 compared to OVACAR8/
NA; #P<0.05 compared to OVACAR8). (C) A transwell assay of OVACAR8/WFDC2 cells in the presence or absence of LY294002 (0.1 μM); photographs were obtained after
18 hrs of incubation. Data are presented as the mean ± sd (*P<0.05). (D) Detection of p-AKT, MMP-2, Vimentin, and E-cadherin in cells treated with LY294002 (20 μmol/L).
(E) A schematic diagram of how WFDC2 promotes cellular metastasis through the AKT-mediated signaling.
Abbreviations: MMP, matrix metalloproteinase; sh, small hairpin; EMT, epithelial–mesenchymal transition.
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promoter of tumor growth.1,2 To be interesting, we had
observed that the ability of ovarian cancer cells to
penetrate ECM was greatly reduced with WFDC2
knockdown in transwell assay. It is well known that
MMPs are most important hydrolytic enzymes for the
degradation of the ECM.7,15,17,22 And the MMPs had
been considered as the necessary proteases in EMT
progression and also an inducer of EMT.7,17,23,24 We
also found a positive correlation of MMP-2 and
WFDC2 not only in cell models, but also in nude
mice xenograft and clinical specimens. So we hope to
discuss the relationship between WFDC2 and MMP-2
expression in promoting EMT in this research
experience.
First, we analyzed the relationship between WFDC2
expression and EMT. EMT is a dynamic process, which is
characterized by a fundamental change in increasing abil-
ity to migrate, as well as the loss of epithelial markers and
the acquisition of mesenchymal markers.8,10,25,26 In this
study, we showed WFDC2 knockdown caused E-cadherin
upregulation and Vimentin downregulation, which indi-
cated that WFDC2 knockdown changed the phenotype of
tumor cells and inhibited the EMT progression of tumor
cells. Next, a WFDC2 overexpression cell model had been
constructed to explore whether WFDC2 promotes the gen-
eration of EMT by regulating the expression of MMP-2.
These results showed that the increasing invasive ability
induced by WFDC2 overexpression could be restored by
treating with siRNA against MMP-2. At the same time, the
EMT phenotype induced by WFDC2 overexpression could
be also reversed by the siMMP-2. This phenomenon sug-
gests MMP-2 was likely to be a downstream target of
WFDC2, and WFDC2 promotes the metastasis and EMT
of ovarian cancer cells by regulating the expression of
MMP-2.
To declare how WFDC2 regulated MMP-2 expression,
we further analyzed the molecular mechanism of WFDC2
in cell metastasis. MMP-2, an important protease in EMT
progression, could be regulated by activating multiple
signal pathways including Smads pathway, ERK-MAPK
pathway, and PI3K-AKT pathway.27–29 In our study, we
had observed that the knockdown of WFDC2 suppressed
the phosphorylation of AKT and the expression of smard3.
To be interesting, LY294002, a PI3K-AKT pathway inhi-
bitor, reverses MMP-2 expression and cell invasion
induced by WFDC2 overexpression. These results indicate
that WFDC2-induced activation of PI3K-AKT signaling
explains its effect on MMP-2 expression and cell motility,
while exactly how WFDC2 activates the PI3K-AKT path-
way needs to be further revealed.
Conclusion
In summary, our study shows that knockdown of
WFDC2 inhibited the EMT progression through activat-
ing the PI3K-AKT signaling, leading to the downregula-
tion of MMP-2 and declined the invasion and metastasis
of ovarian cancer cells, while overexpression of WFDC2
entirely reverses these effects. Since knockdown of
MMP-2 and inhibition of the PI3K-AKT signaling
inhibited the invasion ability of ovarian cancer cells
with WFDC2 overexpression, we propose that both
AKT and MMP-2 are downstream targets of WFDC2
(Figure 4E). Further study is needed to illustrate the
specific role of WFDC2 in the microenvironment
rebuilding of ovarian cancer. WFDC2 overexpression
may be not only a biomarker, but also a therapeutic
target to block the metastasis and recurrence of serous
ovarian cancer.
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WFDC2, WAP four-disulfide core domain 2; EMT,
Epithelial-Mesenchymal Transition; IHC, immunohisto-
chemistry; qPCR, quantitative real-time PCR; NC, nega-
tive control; MMP2, matrix metalloproteinase 2; AKT,
protein kinase B;ERK, extracellular regulated protein
kinases,; ECM, extracellular matrix.
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Table S1 Distribution by tumor characteristics for ovarian cancer
patients







Stage I 26 28.57
Stage II 21 23.08
Stage III 31 34.07






Serous cystadenocarcinoma 46 50.55
Mucinous cystadenocarcinoma 22 24.18
Endometrioid tumor 14 15.38
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